{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:56Z","timestamp":1791113576980,"version":"4.1.0"},"reference-count":57,"publisher":"Japanese Society of Hypertension","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2008]]},"DOI":"10.1291\/hypres.31.59","type":"journal-article","created":{"date-parts":[[2008,3,21]],"date-time":"2008-03-21T05:52:06Z","timestamp":1206078726000},"page":"59-67","source":"Crossref","is-referenced-by-count":75,"title":["Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker"],"prefix":"10.1291","volume":"31","author":[{"given":"Yoshiyuki","family":"FURUMATSU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"NAGASAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodo","family":"TOMIDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"MIKAMI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"KANEKO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"OKADA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"TSUBAKIHARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"IMAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"SHOJI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Russo D, Pisani A, Balletta MM, et al<\/i>: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis<\/i> 1999; 33<\/b>: 851-856.","DOI":"10.1016\/S0272-6386(99)70416-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Russo D, Minutolo R, Pisani A, et al<\/i>: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis<\/i> 2001; 38<\/b>: 18-25.","DOI":"10.1053\/ajkd.2001.25176"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12229-5"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119249"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis<\/i> 2001; 37<\/b>: 677-688.","DOI":"10.1016\/S0272-6386(01)80115-3"},{"issue":"1","key":"6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/j.1552-4604.1993.tb03901.x","volume":"33","year":"1993","ISSN":"https:\/\/id.crossref.org\/issn\/0091-2700","issn-type":"print"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877755"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sato A, Saruta T: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res<\/i> 2001; 29<\/b>: 13-21.","DOI":"10.1177\/147323000102900103"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000022606.52221.2F"},{"issue":"4","key":"10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","volume":"33","author":"ROBERT V","year":"1999","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Harada E, Yoshimura M, Yasue H, et al<\/i>: Aldosterone induces angiotensin-converting−enzyme gene expression in cultured neonatal rat cardiocytes. Circulation<\/i> 2001; 104<\/b>: 137-139.","DOI":"10.1161\/01.CIR.104.2.137"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1674"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.40.573"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091405.00772.6E"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000067463.13172.EA"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.781"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200109203451215"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.03.007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Schjoedt KJ, Rossing K, Juhl TR, et al<\/i>: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int<\/i> 2005; 68<\/b>: 2829-2836.","DOI":"10.1111\/j.1523-1755.2005.00756.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bianchi S, Bigazzi R, Campese VM: Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int<\/i> 2006; 70<\/b>: 2116-2123.","DOI":"10.1038\/sj.ki.5001854"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Schjoedt KJ, Rossing K, Juhl TR, et al<\/i>: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int<\/i> 2006; 70<\/b>: 536-542.","DOI":"10.1038\/sj.ki.5001580"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chrysostomou A, Pedagogos E, MacGregor L, Becker G: Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or wihtout an angiotensin II receptor blocker. Clin J Am Soc Nephrol<\/i> 2006; 1<\/b>: 256-262.","DOI":"10.2215\/CJN.01040905"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pitt B, Zannad F, Remme WJ, et al<\/i>, Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med<\/i> 1999; 341<\/b>: 709-717.","DOI":"10.1056\/NEJM199909023411001"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000044937.95080.E9"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Bakris GL, Williams M, Dworkin L, et al<\/i>: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis<\/i> 2000; 36<\/b>: 646-661.","DOI":"10.1053\/ajkd.2000.16225"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant<\/i> 1998; 13<\/b>: 1682-1685.","DOI":"10.1093\/ndt\/13.7.1682"},{"key":"27","unstructured":"27. Shimizu N, Miyashita H, Koide K, Yoshikawa J: Antipressor effect of spironolactone or thyazide diuretics for essential hypertension: double blind comparative study. Horumon To Rinsho<\/i> 1977; 25<\/b>: 167-174 (in Japanese)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med<\/i> 1983; 309<\/b>: 1543-1546.","DOI":"10.1056\/NEJM198312223092503"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Schwab SJ, Christensen RL, Dougherty K, Klahr S: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med<\/i> 1987; 147<\/b>: 943-944.","DOI":"10.1001\/archinte.147.5.943"},{"issue":"9","key":"30","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1253\/jcj.46.948","volume":"46","year":"1982","ISSN":"https:\/\/id.crossref.org\/issn\/0047-1828","issn-type":"print"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.29.397"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(89)90235-0"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Donovan KL, Coles GA, Williams JD: An ELISA for the detection of type IV collagen in human urine—application to patients with glomerulonephritis. Kidney Int<\/i> 1994; 46<\/b>: 1431-1437.","DOI":"10.1038\/ki.1994.415"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Cameron JS, Blandford G: The simple assessment of selectivity in heavy proteinuria. Lancet<\/i> 1966; 2<\/b>: 242-247.","DOI":"10.1016\/S0140-6736(66)92539-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens<\/i> 2005; 18<\/b>: 44-49.","DOI":"10.1016\/j.amjhyper.2004.06.029"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000438"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.2.448"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Brown NJ, Vaughan DE, Fogo AB: The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol<\/i> 2002; 22<\/b>: 399-406.","DOI":"10.1053\/snep.2002.34725"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.12.2145"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis<\/i> 2002; 39<\/b>: 486-492.","DOI":"10.1053\/ajkd.2002.31392"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Sato A, Suzuki Y, Saruta T: Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res<\/i> 1999; 22<\/b>: 17-22.","DOI":"10.1291\/hypres.22.17"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.971"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.29.211"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. McKelvie RS, Yusuf S, Pericak D, et al<\/i>: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation<\/i> 1999; 100<\/b>: 1056-1064.","DOI":"10.1161\/01.CIR.100.10.1056"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Tang WH, Vagelos RH, Yee YG, et al<\/i>: Neurohormonal and clinical responses to high- versus<\/i> low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol<\/i> 2002; 39<\/b>: 70-78.","DOI":"10.1016\/S0735-1097(01)01714-4"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Price DA, Porter LE, Gordon M, et al<\/i>: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol<\/i> 1999; 10<\/b>: 2382-2391.","DOI":"10.1681\/ASN.V10112382"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Hollenberg NK, Price DA, Fisher ND, et al<\/i>: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int<\/i> 2003; 63<\/b>: 172-178.","DOI":"10.1046\/j.1523-1755.2003.00701.x"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1159\/000045709"},{"key":"49","unstructured":"49. Okonogi H, Nishimura M, Utsunomiya Y, et al<\/i>: Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol<\/i> 2001; 55<\/b>: 357-364."},{"key":"50","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1026"},{"key":"51","unstructured":"51. Nishimura M, Sasaki T, Ohishi A, et al<\/i>: Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol<\/i> 2001; 56<\/b>: 96-103."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Goodfield NE, Newby DE, Ludlam CA, Flapan AD: Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation<\/i> 1999; 99<\/b>: 2983-2985.","DOI":"10.1161\/01.CIR.99.23.2983"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(01)02140-9"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Uzu T, Harada T, Namba T, et al<\/i>: Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens<\/i> 2005; 23<\/b>: 861-865.","DOI":"10.1097\/01.hjh.0000163156.37363.47"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.303"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011119003788"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T07:31:43Z","timestamp":1630913503000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.31.59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.31.59","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008]]}}}